Cervical Cancer - Market Insights, Epidemiology and Market Forecast - 2023

  • ID: 4330706
  • Drug Pipelines
  • 77 pages
  • DelveInsight
1 of 3
Cervical Cancer - Market Insights, Epidemiology and Market Forecast-2023-Global provides an overview of the disease and global market size of the Cervical Cancer for the 7MM (United States, EU5 (France, Germany, Italy, Spain and UK) and Japan. It also includes global historical and forecasted epidemiological data for the diagnosed incident cases of Cervical Cancer from 2013-2023. We estimate that the therapeutic market size for Cervical Cancer will increase at a Compound Annual Growth Rate of 1.39% and will reach up to USD 231.93 million globally in 2023. The global market size for prophylaxis treatment of Cervical Cancer is expected to grow at a CAGR of 0.71% and reach up to USD 2210.9 Million by 2023.

Cervical Cancer needs to be focused more and more because it adversely affects younger women. It is the fourth most common cause of death among women. Cervical Cancer occurs due to the uncontrolled growth of healthy cells in cervix and forms cervical lesions. It spreads to other tissues such as vagina and uterus. Cervical Cancer is caused by inheritance of defects or mutation in genes. Cervical cancer is also caused due to the infection by the Human Papilloma Virus (HPV) which can infect cells on the surface of the skin and those lining the genitals, anus, mouth and throat, but not the blood or internal organs such as the heart or lungs.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by Publisher team of industry experts.

Scope:
  • report covers the disease overview including pathophysiology, symptoms, diagnosis, disease management, and current treatment options.
  • Marketed information including available prescription drugs, its patent and exclusivity details.
  • The report also covers the detailed global historical and forecasted epidemiological data covering United States, EU5 and Japan from 2013-2023.
  • It also provides Market size of Cervical Cancer for United States, EU5 and Japan from 2013 and forecasted Market size to 2023.
  • The report will help in developing business strategies by understanding the trends shaping and driving the global market size of the Cervical Cancer for the 7MM (United States, EU5 (France, Germany, Italy, Spain and UK) and Japan.
  • Identifying patient populations in the 7MM (United States, EU5 (France, Germany, Italy, Spain and UK) and Japan Cervical Cancer market to improve product design, pricing, and launch plans.
  • To understand the future market competition in the 7MM (United States, EU5 (France, Germany, Italy, Spain and UK) and Japan Cervical Cancer therapeutics market, as well as prophylaxis and Insightful review of the key market drivers and barriers.
Note: Please allow up to 24 hours for delivery after payment has been made.
READ MORE
Note: Product cover images may vary from those shown
2 of 3
Report Introduction
Cervical Cancer Disease Overview
  • Types of Cervical cancer
  • Staging of Cervical cancer
  • Pathophysiology
  • Etiology
  • Risk Factors
Diagnosis
Epidemiology and Patient Population of Cervical Cancer
United States
Historical Incident Cases of Cervical Cancer in United States (2013-2015)
Forecasted Incident Cases of Cervical Cancer in United States (2016-2023)
Historical Incident Cases of Cervical Cancer diagnosed by stage in United States (2013-2015)
Forecasted Incident Cases of Cervical Cancer diagnosed by stage in United States (2016-2023)
United Kingdom (UK)
Historical Incident Cases of Cervical Cancer in United Kingdom (UK) (2013-2015)
Forecasted Incident Cases of Cervical Cancer in United Kingdom (UK) (2016-2023)
Germany (GE)
Historical Incident Cases of Cervical Cancer in Germany (2013-2015)
Forecasted Incident Cases of Cervical Cancer in Germany (2016-2023)
Italy (IT)
Historical Incident Cases of Cervical Cancer in Italy (2013-2015)
Forecasted Incident Cases of Cervical Cancer in Italy (2016-2023)
France (FR)
Historical Incident Cases of Cervical Cancer in France (2013-2015)
Forecasted Incident Cases of Cervical Cancer in France (2016-2023)
Spain (SP)
Historical Incident Cases of Cervical Cancer in Spain (2013-2015)
Forecasted Incident Cases of Cervical Cancer in Spain (2016-2023)
Japan (JP)
Historical Incident Cases of Cervical Cancer in Japan (2013-2015)
Forecasted Incident Cases of Cervical Cancer in Japan (2016-2023)
Treatment Landscape
Treatment Algorithm
Treatment by Stages
Cervical Cancer Treatment Regimens
Current Unmet Needs
Cervical Cancer Therapeutic Treatments
Bevacizumab (Avastin)
Advantages & Disadvantages
Product Profile
Efficacy
Safety
Side effects of Drug
Avastin Historical Market Sales 2013-2015
Annual cost of therapy of Avastin
Cervical Cancer Prophylaxis Treatments
Cervarix (Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant)
Advantages & Disadvantages
Product Profile
Efficacy
Safety of Cervarix
Side effects of Drug
Cervarix Historical Market Sales 2012-2015
Cost of therapy of Cervarix
GARDASIL/ GARDASIL 9
Advantages & Disadvantages
Product Profile
Efficacy
Safety
Side effects of Drug
Gardasil Historical Market Sales 2012-2015
Cost of therapy of Gardasil
Pipeline Product (Phase III)
Z-100 (Ancer 20)
Axalimogene filolisbac or AXAL (ADXS11-001)
Gimeracil-Oteracil-Tegafur (S-1, TS-1)
Pipeline Product Analysis
Cervical Cancer Therapeutics Market
Historical Cervical Cancer Therapeutics Market (2013-2015)
Forecasted Cervical Cancer Therapeutics Market (2016-2023)
Global
United States (US)
United Kingdom (UK)
Germany (DE)
Italy (IT)
France (FR)
Spain (SP)
Japan (JP)
Cervical Cancer Prophylaxis Treatment
Historical Cervical Cancer Prophylaxis Treatment (2013-2015)
Forecasted Cervical Cancer Prophylaxis Treatment (2016-2023)
Assumptions and Rationale
Market Drivers
Market Barriers
Appendix
Report Methodology
Consulting Services
Disclaimer
About

List of Tables
Table 1: Historical Incident Cases of Cervical Cancer in United States (2013-2015)
Table 2: Forecasted Incident Cases of Cervical Cancer in United States (2017-2023)
Table 3: Historical Incident Cases of Cervical Cancer diagnosed by Cancer Stage, in United States (2013-2015)
Table 4: Forecasted Incident Cases of Cervical Cancer diagnosed by Cancer Stage, in United States (2017-2023)
Table 5: Historical Incident Cases of Cervical Cancer in United Kingdom (UK) (2013-2015)
Table 6: Forecasted Incident Cases of Cervical Cancer in United Kingdom (UK) (2017-2023)
Table 7: Historical Incident Cases of Cervical Cancer in Germany (2013-2015)
Table 8: Forecasted Incident Cases of Cervical Cancer in Germany (2017-2023)
Table 9: Historical Incident Cases of Cervical Cancer inItaly (2013-2015)
Table 10: Forecasted Incident Cases of Cervical Cancer in Italy (2017-2023)
Table 11: Historical Incident Cases of Cervical Cancer in France (2013-2015)
Table 12: Forecasted Incident Cases of Cervical Cancer in France (2017-2023)
Table 13: Historical Incident Cases of Cervical Cancer in Spain (2013-2015)
Table 14: Forecasted Incident Cases of Cervical Cancer in Spain (2017-2023)
Table 15: Historical Incident Cases of Cervical Cancer in Japan (2013-2015)
Table 16: Forecasted Incident Cases of Cervical Cancer in Japan (2017-2023)
Table 17: Cervical Cancer Therapeutics Market in Global (2013-2023)
Table 18: Historical Cervical Cancer Therapeutics Market in United States (2013-2015)
Table 19: Forecasted Incident Cases of Cervical Cancer in United States (2017-2023)
Table 20: Historical Cervical Cancer Therapeutics Market in United Kingdom (2013-2015)
Table 21: Forecasted Cervical Cancer Therapeutics Market in United Kingdom (2017-2023)
Table 22: Historical Cervical Cancer Therapeutics Market in Germany (2013-2015)
Table 23: Forecasted Cervical Cancer Therapeutics Market in Germany (2017-2023)
Table 22: Historical Cervical Cancer Therapeutics Market in Italy (2013-2015)
Table 23: Forecasted Cervical Cancer Therapeutics Market in Italy (2017-2023)
Table 24: Historical Cervical Cancer Therapeutics Market in France (2013-2015)
Table 25: Forecasted Cervical Cancer Therapeutics Market in France (2017-2023)
Table 24: Historical Cervical Cancer Therapeutics Market in Japan (2013-2015)
Table 25: Forecasted Cervical Cancer Therapeutics Market in Japan (2017-2023)
Table 26: Historical Global Market of Cervical Cancer Prophylaxis Treatment in USD, Million (2013-2015)
Table 27: Forecasted Global Market of Cervical Cancer Prophylaxis Treatment in USD, Million (2017-2023)

List of Figures
Figure 1: Pathophysiology of Cervical Cancer, 2017
Figure 2: Risk Factors of Cervical Cancer, 2017
Figure 3: Historical Incident Cases of Cervical Cancer in United States (2013-2015)
Figure 4: Forecasted Incident Cases of Cervical Cancer in United States (2017-2023)
Figure 5: Historical Incident Cases of Cervical Cancer in United Kingdom (UK) (2013-2015)
Figure 6: Forecasted Incident Cases of Cervical Cancer in United Kingdom (UK) (2017-2023)
Figure 7: Historical Incident Cases of Cervical Cancer in Germany (2013-2015)
Figure 8: Forecasted Incident Cases of Cervical Cancer in Germany (2017-2023)
Figure9: Historical Incident Cases of Cervical Cancer inItaly (2013-2015)
Figure10: Forecasted Incident Cases of Cervical Cancer in Italy (2017-2023)
Figure11: Historical Incident Cases of Cervical Cancer in France (2013-2015)
Figure12: Forecasted Incident Cases of Cervical Cancer in France (2017-2023)
Figure13: Historical Incident Cases of Cervical Cancer in Spain (2013-2015)
Figure14: Forecasted Incident Cases of Cervical Cancer in Spain (2017-2023)
Figure15: Historical Incident Cases of Cervical Cancer in Japan (2013-2015)
Figure16: Forecasted Incident Cases of Cervical Cancer in Japan (2017-2023)
Figure 11: Treatment Algorithm for Cervical Cancer, 2017
Figure 12: Treatment for patients with Stage IA1 of Cervical Cancer, 2017
Figure 13: Treatment for patients with Stage IA2 of Cervical Cancer, 2017
Figure 14: Treatment for patients with Stage IB1 of Cervical Cancer, 2017
Figure 15: Treatment for patients with Stage IB2 to Stage IVA of Cervical Cancer, 2017
Figure 16: Treatment for patients with Stage IVB of Cervical Cancer, 2017
Figure 18: Global Cervical Cancer Therapeutics Market (2013-2023)
Figure13: Historical Cervical Cancer Therapeutics Market in United States (2013-2015)
Figure 14: Forecasted Cervical Cancer Therapeutics Market in United States (2017-2023)
Figure15: Historical Cervical Cancer Therapeutics Market in United Kingdom (2013-2015)
Figure 16: Forecasted Cervical Cancer Therapeutics Market in United Kingdom (2017-2023)
Figure17: Historical Cervical Cancer Therapeutics Market in Germany (2013-2015)
Figure18: Forecasted Cervical Cancer Therapeutics Market in Germany (2017-2023)
Figure19: Historical Cervical Cancer Therapeutics Market in Italy (2013-2015)
Figure 20: Forecasted Cervical Cancer Therapeutics Market in Italy (2017-2023)
Figure 21: Historical Cervical Cancer Therapeutics Market in France (2013-2015)
Figure22: Forecasted Cervical Cancer Therapeutics Market in France (2017-2023)
Figure 23: Historical Cervical Cancer Therapeutics Market in Spain (2013-2015)
Figure24: Forecasted Cervical Cancer Therapeutics Market in Spain (2017-2023)
Figure 25: Historical Cervical Cancer Therapeutics Market in Japan (2013-2015)
Figure26: Forecasted Cervical Cancer Therapeutics Market in Japan (2017-2023)
Figure 27: Historical Global Market of Cervical Cancer Prophylaxis Treatment in USD, Million (2013-2015)
Figure 28: Forecasted Global Market of Cervical Cancer Prophylaxis Treatment in USD, Million (2017-2023)
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll